INTRODUCTION
The emergence of coronavirus disease 2019 (COVID-19) in December 2019 caused unprecedented
challenges to healthcare worldwide. Although at the beginning of the COVID-19 pandemic
it was projected that Africa would suffer a huge pandemic, the reality is that the
number of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections
and deaths from COVID-19 have not been as large as projected. Africa has currently
reported ∼4.6 million confirmed cases of SARS-CoV-2 infection against a global total
of 190.5 million confirmed infections and 107,000 deaths against the global total
of 4 million deaths from COVID-19, with a contribution of 2.4% and 2.7% of all confirmed
SARS-CoV-2 infections and COVID-19 deaths, respectively (1). The reasons for this
may include the relatively youthful population of the region, genetic factors, climatic
conditions, high exposure to other infectious diseases with the development of trained
immunity, and use of COVID-19 mitigation measures very early in the evolution of the
COVID-19 pandemic (2). However, lack of testing for diagnosis or poor access to healthcare
facilities with many deaths outside such facilities may also influence these estimates.
The COVID-19 pandemic has caused global devastation among high-income and low- and
middle-income countries (LMICs). In Africa and other LMICs, the direct impact including
COVID-related illness and deaths as well as the indirect effects on economies, other
health-related conditions, education, and social services have been overwhelming and
are likely to endure, threatening to shape the future of its population.
This pandemic poses challenges to the well-being of both adults and children in Africa,
which is made more profound by weak health systems, preexisting poor population health,
and low socioeconomic status pervasive in the continent. Also, high exposure to potentially
harmful environmental factors such as tobacco smoke or air pollution may be associated
with a greater risk of severe COVID-19. Furthermore, the ability of health systems
to deal with increasing numbers of people with COVID-related illness and to upscale
and widely implement vaccination against SARS-CoV-2 is a challenge. However, within
these challenges also lies opportunities for the continent to leverage this health
crisis to improve the lives of its people. The ability to mitigate this pandemic requires
a multifaceted approach embracing global partnerships and alliances.
ADULT LUNG HEALTH IN AFRICA IN THE CONTEXT OF COVID-19
Chronic respiratory diseases (CRDs), including asthma and chronic obstructive pulmonary
disease (COPD), are common and rising public health concerns in Africa (3, 4). These
diseases were relatively neglected with no public health programs in place for them
in most countries in Sub-Saharan Africa (sSA) (5). Consequently, the provision of
healthcare for CRDs such as asthma and COPD has been suboptimal even before the COVID-19
pandemic. The pandemic has further compromised the situation and negatively impacted
care and treatment for these diseases. Most guidelines recommend that pulmonary function
tests should be limited to the most essential tests when possible for fear of transmission
of SARS-CoV-2 (6). This recommendation is likely to constrain efforts that were being
made to promote spirometry testing in sSA and will further compromise the diagnosis
of CRDs in the continent (7).
We hypothesize that in the African setting, the COVID-19 pandemic has reduced the
number of people diagnosed with asthma, worsening the already existing wide gaps between
prevalent cases of asthma and those accessing appropriate care and treatment for their
disease for several reasons. These reasons include inadequate services for asthma
as health resources are diverted to the COVID-19 response as well as fear of a diagnosis
of COVID-19 and the attendant consequences, including isolation, keeping people away
from healthcare facilities for fear of infection with SARS-CoV-2 infection, which
is perceived by the population as fertile grounds for the transmission of this virus.
Patients with asthma exacerbations who arrive at healthcare facilities may have delayed
care for their disease as they are screened and tested for SARS-CoV-2 infection and
may be at increased risk of acquiring infection with this virus if they are placed
in holding areas where persons suspected to have COVID-19 are isolated as they await
their COVID-19 test results. These interactions have not been studied in the African
setting, and we urge African researchers, their partners, and funders to prioritize
this area of research to gather the evidence needed to develop robust mitigation measures.
It has been documented that people with chronic respiratory disease are at increased
risk of developing severe disease when infected with SARS-CoV-2 (8). Data in the African
setting are, however, sparse, and it remains unclear if people with asthma and COPD,
especially those with COPD unrelated to tobacco smoking and people with tuberculosis
(TB)-associated chronic lung disease, which are common forms of chronic respiratory
disease in Africa, have an elevated risk of severe COVID-19.
Similarly, there is a high burden of the human immunodeficiency virus (HIV)-associated
disease, especially in sSA; HIV-infected people, especially those whose disease is
not well controlled with antiretroviral therapy or those with comorbidities such as
diabetes or renal impairment, may be at increased risk for developing severe COVID-19
(9). Other underlying illnesses that place people at risk for developing severe COVID-19
are common in Africa. Cardiovascular disease including hypertension is one of the
commonest noncommunicable diseases in the African population (10). Diabetes and obesity
are increasingly emerging as important chronic illnesses in African populations (11).
Each of these places individuals at increased risk for developing severe COVID-19.
Acute lower respiratory infections (ALRIs) are more common in LMICs, with ∼70% occurring
in South Asia and sSA (12). Pneumonia due to COVID-19 may be difficult to distinguish
from bacterial community-acquired pneumonia. The lack of diagnostic tests for SARS-CoV-2
in the early days of the pandemic might have delayed the diagnosis and optimal management
of bacterial pneumonia. Avoidance of medical settings by patients might have led to
the late diagnosis of pneumonia from other causes and a consequent increase in pneumonia-related
mortality overall.
The COVID-19 outbreak has again brought the weaknesses of health systems in Africa
to the forefront. In emergency departments of many hospitals across sSA, there is
a lack of equipment and commodities, such as pulse oximeters and oxygen that are critical
for the identification and treatment of people with serious lung disease. This situation
implies that outcomes for people presenting to these facilities with COVID-19 and
other respiratory emergencies, including asthma and COPD exacerbations, are likely
to be poor.
CHILD LUNG HEALTH IN AFRICA IN THE CONTEXT OF COVID-19
Respiratory illnesses remain a predominant cause of morbidity and mortality in African
children, from both infectious causes and chronic noncommunicable disease. As children
constitute a third to half of the African population, this comprises a large burden
of illness. Pneumonia and tuberculosis disease remain key challenges for child health,
whereas asthma is the commonest noncommunicable disease in children and adolescents.
African children have been largely spared from moderate or severe illness with SARS-CoV-2
through the COVID-19 pandemic, as has occurred globally, but the indirect effects
have substantially impacted child health.
The incidence and severity of childhood pneumonia have reduced substantially with
socioeconomic improvement, improved immunization strategies, particularly pneumococcal
conjugate vaccine (PCV) and Haemophilus influenzae type b conjugate vaccine (Hib),
and better prevention and management of HIV. Nevertheless, pneumonia remains the commonest
cause of death in children under 5 yr outside the neonatal period, with almost 800,000
deaths in 2018, with more than half of the deaths occurring in Africa or Southeast
Asia (12, 13).
Childhood TB is common in Africa and has been reported to contribute up to 20% of
the overall caseloads (14), although this is probably an underestimate given the challenges
in confirming TB in children and lack of notification of childhood cases. Mycobacterium
tuberculosis has increasingly been recognized as a pathogen in the context of acute
pneumonia in children, comprising a large proportion of cases.
Factors associated with the high burden and severity of respiratory disease in African
children also include high exposure to air pollution or tobacco smoke, under-resourced
health systems, and lack of access to effective preventive or management strategies.
Furthermore, early life respiratory infection, particularly pneumonia or TB, may lead
to a long-term impairment of health, setting a trajectory for the development of CRD
through the course of life (15).
Asthma is the commonest chronic disease in African children, with an increasing prevalence
in both urban and rural settings. Although childhood asthma was regarded as rare in
Africa, global epidemiological studies have shown that the prevalence in African children
is similar or higher than the global average (16). Furthermore, asthma in Africa may
be frequently undiagnosed, untreated, and more severe (17). Access to routine health
services and follow-up during the pandemic may have compromised care of these children
further. HIV-associated chronic lung diseases or bronchiectasis or bronchiolitis obliterans
following lower respiratory tract infection or TB are other causes of chronic respiratory
illness in African children.
Although children and adolescents constitute a very small proportion of cases of COVID-19
and of COVID-associated mortality in Africa, similar to the patterns seen globally,
the indirect effects on child health have been substantial. These include disruptions
in delivery of essential healthcare services such as immunization and HIV or TB programs,
increasing poverty levels, disrupted schooling, lack of access to school feeding schemes,
and diversion of resources away from maternal and child health to adult COVID responses.
With a large informal economic sector with little social protection in Africa, levels
of poverty and hunger are increasing at an alarming rate, increasing the susceptibility
of children to severe pneumonia from other pathogens, which is of concern.
However, the use of nonpharmacological interventions, including universal mask wearing,
social distancing, and hand hygiene, has reduced the incidence of influenza or respiratory
syncytial virus-related illness, with reductions in a number of cases and hospitalization
of children. Nevertheless, late presentation with severe disease may occur as families
may be reluctant to attend health facilities in the context of COVID-19 or these may
be inaccessible. Parental or family loss due to COVID-19 has compounded the effects
on child health. While immunization program against COVID-19 has been initiated in
many African countries, the rollout is slow (18). Greater coverage is urgently needed
to protect populations including children and adolescents, who may be indirectly protected
with high coverage of adult population groups.
TUBERCULOSIS AND COVID-19 IN AFRICA: WHAT HAS HAPPENED?
Sub-Saharan Africa bears a disproportionate burden of tuberculosis. It is currently
estimated that ∼14% of the global population of ∼7.8 billion people live in sSA; however,
in 2019, this region accounted for 25% of all incident cases of TB in the world (19).
The drivers of the large burden of TB in the African setting include the concurrent
HIV epidemic and rampant poverty. Nearly 75% of all people living with HIV are in
sSA (20), and of the 736 million people who lived on less than $1.90 in 2015, 413
million (56%) lived in sSA (21). The link between poverty and TB has been firmly established
and known for nearly a century, and it is therefore not surprising that Africa, with
a large proportion of people living in extreme poverty, suffers a high burden of TB.
An important question that needs to be addressed is the impact that COVID-19 has had
on the TB epidemic in the African setting and what may be expected to happen as the
COVID-19 pandemic continues to evolve. The first major concern has been the influence
of COVID-19 on TB case findings. As a result of both societal fear of a new disease
that had been depicted to be highly lethal and the mitigation measures put in place
to protect society and the healthcare system, TB case findings declined significantly.
Tuberculosis surveillance data from high TB-endemic settings have revealed significant
declines in TB notification between 2019 (the pre-COVID era) and 2020 (the COVID era)
(22). The decline in TB notification in the African settings has been of the order
of ∼20% (23, 24). The decline in TB notifications has been attributed to disruption
in TB service provisions, some of which have been related to closure of facilities
that provide TB services and redirection of resources, including human, financial,
and equipment (such as the Xpert platforms and others) to the COVID-19 response to
confront a public health threat that was perceived to be more urgent and bigger. In
addition, travel restrictions and a fear of health facilities have contributed to
alterations in health-seeking behavior of the population. The full impact of these
developments is not yet known, but it has been projected that TB incidence and deaths
will rise globally to set the world back by several years in the fight against this
age-old disease.
In Sub-Saharan Africa, it has been projected that COVID-19 will lead to economic declines,
with shrinkage of the gross domestic product of African countries of up to 1.4% with
smaller economies contracting by a margin of up to 7.8% that will increase poverty
rates (25). The rise in poverty in Africa because of the COVID-19 pandemic implies
a rise in the burden of TB. The second effect of the COVID-19 pandemic is on treatment
outcomes. With disruptions in TB service provision and the hurdles occasioned by COVID-19
mitigation measures in accessing health services combined with societal fear of health
services, disruptions in TB treatment were expected to become more common. We need
to see if this projection will be confirmed as national TB programs carry out cohort
analysis of treatment outcomes of persons diagnosed with TB in 2020 and 2021 (in the
COVID-19 era) to allow for comparisons to be made with those diagnosed and placed
on treatment in the pre-COVID period. Preliminary data from Kenya, Malawi, and Zambia
suggest that TB treatment outcomes in the COVID-19 era were slightly better than in
the pre-COVID-19 era (26).
Third, there have been concerns that persons with current or previous TB may have
a worse COVID-19 disease clinical course than those without these conditions. The
data so far suggests that this may be so (26), which is extremely worrying for countries
in Sub-Saharan Africa with a large burden of TB, highlighting the need to develop
robust mechanisms to protect these individuals from acquiring SARS-CoV-2 infections
and consequently developing severe disease. Prioritizing these people in vaccination
programs may be very helpful.
In a continent that is struggling with a myriad of health problems on the background
of very weak health systems, the COVID-19 pandemic could not have come at a worse
time. The effect of this pandemic on TB is expected to be enormous and will add to
the woes of a continent that has already been off track with its efforts to achieve
End TB Strategy targets. All is not lost, however, and with concerted efforts including
advocacy efforts to ensure African governments allocate sufficient resources to build
and sustain robust and resilient health systems, the expected trajectory of the TB
epidemic in Africa during and after the COVID-19 pandemic can be reset to get the
African continent to reach the targets of the End TB Strategy. African governments
must address the social determinants of TB. Now is the time to ramp up efforts to
lift people out of poverty in Africa. On the other hand, national TB programs, TB
researchers in Africa, communities, and other stakeholders need to develop, test,
and scale up innovations to expand TB case findings in Africa and to ensure that all
people on treatment for TB are supported throughout their TB journey and beyond. Now
is the time to step up the fight against this disease. Africa should not and must
not be left behind in the fight against TB, COVID-19 notwithstanding.
STRATEGIES TO MITIGATE THE COVID-19 PANDEMIC: WHERE WE ARE AND WHERE WE NEED TO BE
Mitigation strategies for the COVID-19 pandemic aim to slow the spread of the disease
and protect the population while being cognizant of the need to minimize the impact
of these strategies on the well-being of the people they aim to protect. Safe hygiene
practices, physical distancing, and mask wearing are fundamental to any mitigation
action and have been adopted globally to curb the spread of SARS-CoV-2. Universal
mask wearing has been found to be a highly effective practice that reduces transmission
in both experimental models and real-life situations (27, 28). When adhered to, mask
wearing also contributes to the reduced spread of other respiratory diseases including
influenza virus or respiratory syncytial virus. However, adherence to mask-wearing
has varied, being politicized in some parts, unenforced in others, or just simply
ignored.
Lockdown or mandatory stay-at-home measures as a mitigation strategy truncate the
spread of the virus and protect the health system but have adverse social, economic,
educational, and health consequences (29). The adverse economic impacts of COVID-19-related
lockdowns have been found to be more profound in the African setting due to high rates
of poverty, high reliance on daily wages, and lack of social safety nets (30). Furthermore,
reports of increases in sex-based violence during lockdowns in many parts of Africa
and non-COVID deaths due to limited access to healthcare services have been documented
(31, 32). Therefore, lockdown as a COVID-19 mitigation strategy has not worked well
in Africa and in many instances its enforcement has been met with protests and crackdowns
resulting in further loss of lives. Lockdowns disproportionately affect the poor and
widen the already existing inequities within these societies.
Mitigating the pandemic must of necessity include the provision of adequate healthcare
services to treat all people with COVID-19, which remains a challenge within Africa’s
fragile health systems. Inadequate supply of oxygen was a prepandemic challenge in
many parts of Africa, which has been exacerbated by the pandemic as increased demand
for oxygen far outstripped supply. Although some efforts have been made to mitigate
the deficits in oxygen supply with some African countries, such as Nigeria and Malawi
having made some strides in improving oxygen supply by establishing new infrastructure
for production and delivery, these efforts have not been enough. One major health
need in the COVID-19 pandemic is the availability of critical care services including
care and treatment of respiratory failure using supportive ventilation. Across sSA,
the availability of critical care beds and associated resources for the provision
of care and treatment of critically ill patients with COVID-19 is dismal. This calls
for the mobilization of resources not only for infrastructural development but also
for capacity building. Trained healthcare workers in this area are limited, and task
shifting for critical care has proven feasible in Africa and requires further consideration
(33).
Vaccination, which is considered one of the most cost-effective strategies for mitigating
and containing this pandemic, has underscored the global inequities that exist today.
While countries such as Canada, United Kingdom, and Israel have achieved nearly 70%
vaccination rates, Africa is yet to reach the 3% mark targeted by the World Health
Organization (WHO) under the COVID-19 Vaccines Global Access (COVAX) facility as of
mid-July 2021. Indeed, most African countries have vaccinated <1% of the population
with one dose of the vaccine.
The decisive and proactive measures taken by the African Center for Disease Control
to mitigate this pandemic, which included the Partnership to Accelerate COVID-19 Testing
(PACT) and more recently procurement and equitable distribution of donated vaccines
through the COVAX facility, are commendable. The early development of a continent-wide
African strategy endorsed by African leaders in the early phases of this pandemic
may have contributed to the unexpected low numbers of COVID-19 cases and related deaths
in Africa. However, much more needs to be done with regard to vaccine access and widespread
effective implementation in Africa. COVAX will receive ∼600 million doses of the vaccine,
which can cover only a third of the African population, implying that countries need
to purchase vaccines to meet additional needs. Vaccine availability, affordability,
and implementation will remain key challenges for the African setting, and there is
a need for the global community to consider additional strategies to scale up vaccine
coverage for poorer African countries. In addition, vaccine hesitancy in the African
setting will need to be decisively dealt with to ensure vaccines made available through
the various initiatives are taken up by the population in a timely manner. Addressing
vaccine hesitancy in high-context societies of Africa where key opinion leaders sway
behavior regardless of scientific rationale is an important mitigation strategy that
requires public health action. The rapid spread of conspiracy theories through the
wide penetration of social media in Africa must be matched by alternative messaging
that is grounded in local realities to enhance vaccine uptake when vaccines become
more available.
As rich countries begin to emerge from this pandemic due to confidence in the high
rates of vaccination, Africa must not be left behind. The spread of SARS-CoV-2 from
China to a global pandemic serves as a lesson and reminder that global health is everyone’s
business.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
O.B.O., B.H.M.N., H.J.Z., R.M., and J.C. drafted manuscript; O.B.O., B.H.M.N., H.J.Z.,
R.M., and J.C. edited and revised manuscript; O.B.O., B.H.M.N., H.J.Z., R.M., J.C.,
and J.A. approved final version of manuscript.